{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:50:54Z","timestamp":1788814254740,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR 205\/The Adrenal: Central Relais in Health"],"award-info":[{"award-number":["TRR 205\/The Adrenal: Central Relais in Health"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Disease"],"award-info":[{"award-number":["Disease"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstracts<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Somatostatin-receptor (SSTR)\u2014targeting PET\/CT is widely used for diagnosis and disease monitoring of pheochromocytoma \/ paraganglioma (PPGL). The aim of this study was to assess the potential of the novel SSTR-targeting tracer [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE in diagnosing PPGL by comparing imaging parameters to tumor marker levels and secretory activity in a small cohort of patients diagnosed with this rare tumor type.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 34 patients with histologically confirmed PPGL who underwent [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE-PET\/CT at LMU University Hospital Munich between 10\/2020 and 02\/2024 as well as hormonal laboratory analysis within up to 100\u00a0days. Imaging parameters\u00a0\u2014\u00a0standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion uptake (TLU)\u00a0\u2014\u00a0were analyzed. Uptake was normalized to liver background (SUVmaxr, SUVmeanr). Radioligand uptake of biochemical subtypes and genotypes was compared with Mann-Whitney-U test. Correlation was tested using Spearman\u00b4s rank correlation test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The patient-based detection rate of [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE-PET was 96.6%. A moderate correlation was found between MTV and TLU with chromogranin A (r\u2009=\u20090.570-0.608, p\u2009&lt;\u20090.005) and with biochemical secretion (r\u2009=\u20090.466-0.576, p\u2009&lt;\u20090.05). Hereditary PPGL with Cluster 1 genotype showed stronger [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE uptake compared to sporadic PPGL (SUVmeanr: p\u2009=\u20090.032; SUVmaxr: p\u2009=\u20090.051). A subgroup comparison with [\u2076\u2078Ga]Ga-DOTATOC-PET\/CT revealed no significant difference in uptake metrics or tumor-to-background ratios.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This is the first clinical evaluation of [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE-PET\/CT in patients with PPGL.\u00a0MTV and TLU measured with [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE-PET\/CT correlated well with the tumor marker chromogranin A in serum and with (nor)metanephrines in urine and plasma. Within the limits imposed by the small cohort, our results suggest that TLU and MTV in [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE-PET\/CT could be used as SSTR imaging biomarker for monitoring of disease progression and secretory activity in patients with PPGL.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07341-9","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T23:45:16Z","timestamp":1748562316000},"page":"5175-5188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["[18F]SiTATE-PET\/CT for detection of pheochromocytomas and paragangliomas: comparison of biochemical secretion, genotype and imaging metrics"],"prefix":"10.1007","volume":"52","author":[{"given":"Meike","family":"Onkes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dahlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Gesenhues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean Ira G.","family":"Gacula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fania R. O. L.","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"St\u00fcfchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lottspeich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias K.","family":"Auer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessa","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Braunschweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz-Josef","family":"Gildehaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Schmid-Tannwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pfluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph J.","family":"Auernhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"N\u00f6lting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bidlingmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6157-0363","authenticated-orcid":false,"given":"Friederike","family":"V\u00f6lter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"4","key":"7341_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.7326\/0003-4819-134-4-200102200-00016","volume":"134","author":"K Pacak","year":"2001","unstructured":"Pacak K, et al. Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Ann Intern Med. 2001;134(4):315\u201329.","journal-title":"Ann Intern Med"},{"key":"7341_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1749-6632.2002.tb04410.x","volume":"970","author":"JW Lenders","year":"2002","unstructured":"Lenders JW, Pacak K, Eisenhofer G. New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholamines. Ann N Y Acad Sci. 2002;970:29\u201340.","journal-title":"Ann N Y Acad Sci"},{"key":"7341_CR3","doi-asserted-by":"publisher","unstructured":"B\u00edlek R, Vl\u010dek P, \u0160afa\u0159\u00edk L, Michalsk\u00fd D, Nov\u00e1k K, Du\u0161kov\u00e1 J, V\u00e1clav\u00edkov\u00e1 E, Widimsk\u00fd J Jr, Zelinka T. Chromogranin A in the laboratory diagnosis of pheochromocytoma and paraganglioma. Cancers (Basel). 2019;11(4):586.\u00a0https:\/\/doi.org\/10.3390\/cancers11040586.","DOI":"10.3390\/cancers11040586"},{"issue":"2","key":"7341_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/ncpendmet0396","volume":"3","author":"K Pacak","year":"2007","unstructured":"Pacak K, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab. 2007;3(2):92\u2013102.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"11","key":"7341_CR5","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","volume":"287","author":"JW Lenders","year":"2002","unstructured":"Lenders JW, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427\u201334.","journal-title":"JAMA"},{"issue":"6","key":"7341_CR6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.4158\/EP161718.RA","volume":"23","author":"G Gupta","year":"2017","unstructured":"Gupta G, Pacak K. Precision medicine: an update on genotype\/biochemical phenotype relationships in pheochromocytoma\/paraganglioma patients. Endocr Pract. 2017;23(6):690\u2013704.","journal-title":"Endocr Pract"},{"issue":"12","key":"7341_CR7","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1373\/clinchem.2014.224832","volume":"60","author":"G Eisenhofer","year":"2014","unstructured":"Eisenhofer G, Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. Clin Chem. 2014;60(12):1486\u201399.","journal-title":"Clin Chem"},{"issue":"5","key":"7341_CR8","doi-asserted-by":"publisher","first-page":"E1223","DOI":"10.1152\/ajpendo.90591.2008","volume":"295","author":"G Eisenhofer","year":"2008","unstructured":"Eisenhofer G, et al. Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. Am J Physiol Endocrinol Metab. 2008;295(5):E1223\u201333.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"7341_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1373\/clinchem.2004.045484","volume":"51","author":"G Eisenhofer","year":"2005","unstructured":"Eisenhofer G, et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem. 2005;51(4):735\u201344.","journal-title":"Clin Chem"},{"issue":"2","key":"7341_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1210\/jc.2010-1588","volume":"96","author":"G Eisenhofer","year":"2011","unstructured":"Eisenhofer G, et al. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. J Clin Endocrinol Metab. 2011;96(2):375\u201384.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"7341_CR11","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1210\/jc.2016-3829","volume":"102","author":"C Pamporaki","year":"2017","unstructured":"Pamporaki C, et al. Characteristics of pediatric vs adult pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2017;102(4):1122\u201332.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7341_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","volume":"43","author":"S N\u00f6lting","year":"2022","unstructured":"N\u00f6lting S, et al. Personalized management of pheochromocytoma and paraganglioma. Endocr Rev. 2022;43(2):199\u2013239.","journal-title":"Endocr Rev"},{"issue":"2","key":"7341_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrendo.2014.188","volume":"11","author":"J Favier","year":"2015","unstructured":"Favier J, Amar L, Gimenez-Roqueplo A-P. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. 2015;11(2):101\u201311.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"7341_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31(2):181\u201393.","journal-title":"Cancer Cell"},{"issue":"1","key":"7341_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.trecan.2017.11.001","volume":"4","author":"I Jochmanova","year":"2018","unstructured":"Jochmanova I, Pacak K. Genomic landscape of pheochromocytoma and paraganglioma. Trends Cancer. 2018;4(1):6\u20139.","journal-title":"Trends Cancer"},{"issue":"20","key":"7341_CR16","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","volume":"20","author":"N Burnichon","year":"2011","unstructured":"Burnichon N, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011;20(20):3974\u201385.","journal-title":"Hum Mol Genet"},{"key":"7341_CR17","doi-asserted-by":"publisher","first-page":"138573","DOI":"10.1155\/2015\/138573","volume":"2015","author":"A Luchetti","year":"2015","unstructured":"Luchetti A, et al. Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis. Int J Endocrinol. 2015;2015:138573.","journal-title":"Int J Endocrinol"},{"key":"7341_CR18","doi-asserted-by":"publisher","unstructured":"Gieldon L, William D, Hackmann K, Jahn W, Jahn A, Wagner J, Rump A, Bechmann N, N\u00f6lting S, Kn\u00f6sel T, Gudziol V, Constantinescu G, Masjkur J, Beuschlein F, Timmers HJ, Canu L, Pacak K, Robledo M, Aust D, Schr\u00f6ck E, Eisenhofer G, Richter S, Klink B. Optimizing genetic workup in pheochromocytoma and paraganglioma by integrating diagnostic and research approaches. Cancers (Basel). 2019;11(6):809.\u00a0https:\/\/doi.org\/10.3390\/cancers11060809.","DOI":"10.3390\/cancers11060809"},{"key":"7341_CR19","doi-asserted-by":"publisher","unstructured":"Jiang J, Zhang J, Pang Y, Bechmann N, Li M, Monteagudo M, Calsina B, Gimenez-Roqueplo AP, N\u00f6lting S, Beuschlein F, Fassnacht M, Deutschbein T, Timmers HJLM, \u00c5kerstr\u00f6m T, Crona J, Quinkler M, Fliedner SMJ, Liu Y, Guo J, Li X, Guo W, Hou Y, Wang C, Zhang L, Xiao Q, Liu L, Gao X, Burnichon N, Robledo M, Eisenhofer G. Sino-European differences in the genetic landscape and clinical presentation of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2020;105(10):dgaa502.\u00a0https:\/\/doi.org\/10.1210\/clinem\/dgaa502.","DOI":"10.1210\/clinem\/dgaa502"},{"issue":"11","key":"7341_CR20","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.tem.2017.08.001","volume":"28","author":"D Ta\u00efeb","year":"2017","unstructured":"Ta\u00efeb D, Pacak K. New Insights into the nuclear imaging phenotypes of cluster 1 pheochromocytoma and paraganglioma. Trends Endocrinol Metab. 2017;28(11):807\u201317.","journal-title":"Trends Endocrinol Metab"},{"issue":"8","key":"7341_CR21","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","volume":"38","author":"JWM Lenders","year":"2020","unstructured":"Lenders JWM, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38(8):1443\u201356.","journal-title":"J Hypertens"},{"issue":"7","key":"7341_CR22","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.2967\/jnumed.114.149583","volume":"56","author":"S Niedermoser","year":"2015","unstructured":"Niedermoser S, et al. In Vivo Evaluation of 1\u2078F-SiFAlin-Modified TATE: A Potential Challenge for \u2076\u2078Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET. J Nucl Med. 2015;56(7):1100\u20135.","journal-title":"J Nucl Med"},{"issue":"19","key":"7341_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s10354-012-0130-z","volume":"162","author":"M Sorschag","year":"2012","unstructured":"Sorschag M, Malle P, Gallowitsch H-J. Nuclear medicine in NET. Wien Med Wochenschr. 2012;162(19):416\u201322.","journal-title":"Wien Med Wochenschr"},{"issue":"11","key":"7341_CR24","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/nprot.2012.109","volume":"7","author":"C W\u00e4ngler","year":"2012","unstructured":"W\u00e4ngler C, et al. One-step (18)F-labeling of peptides for positron emission tomography imaging using the SiFA methodology. Nat Protoc. 2012;7(11):1946\u201355.","journal-title":"Nat Protoc"},{"issue":"5","key":"7341_CR25","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.7150\/thno.31806","volume":"9","author":"CM Waldmann","year":"2019","unstructured":"Waldmann CM, et al. The search for an alternative to [(68)Ga]Ga-DOTA-TATE in neuroendocrine tumor theranostics: current state of (18)F-labeled somatostatin analog development. Theranostics. 2019;9(5):1336\u201347.","journal-title":"Theranostics"},{"issue":"12","key":"7341_CR26","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1038\/s41596-020-00407-y","volume":"15","author":"S Lindner","year":"2020","unstructured":"Lindner S, et al. Radiosynthesis of [(18)F]SiFAlin-TATE for clinical neuroendocrine tumor positron emission tomography. Nat Protoc. 2020;15(12):3827\u201343.","journal-title":"Nat Protoc"},{"key":"7341_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.nucmedbio.2020.07.008","volume":"88\u201389","author":"S Lindner","year":"2020","unstructured":"Lindner S, et al. Automated production of [(18)F]SiTATE on a Scintomics GRP\u2122 platform for PET\/CT imaging of neuroendocrine tumors. Nucl Med Biol. 2020;88\u201389:86\u201395.","journal-title":"Nucl Med Biol"},{"key":"7341_CR28","doi-asserted-by":"publisher","unstructured":"Kunte SC, Wenter V, Toms J, Lindner S, Unterrainer M, Eilsberger F, Jurkschat K, W\u00e4ngler C, W\u00e4ngler B, Schirrmacher R, Tiling MW, Sheikh GT, Mehrens D, Brendel M, R\u00fcbenthaler J, Auernhammer CJ, Spitzweg C, Unterrainer LM, Holzgreve A. PET\/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE - first clinical experiences. Eur J Nucl Med Mol Imaging. 2025;52(3):900\u201312. https:\/\/doi.org\/10.1007\/s00259-024-06944-y.","DOI":"10.1007\/s00259-024-06944-y"},{"issue":"11","key":"7341_CR29","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1007\/s00259-021-05351-x","volume":"48","author":"L Beyer","year":"2021","unstructured":"Beyer L, et al. Dosimetry and optimal scan time of [18F]SiTATE-PET\/CT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2021;48(11):3571\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"7341_CR30","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1007\/s00259-023-06315-z","volume":"50","author":"M Unterrainer","year":"2023","unstructured":"Unterrainer M, et al. Next-generation PET\/CT imaging in meningioma\u2014first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE. Eur J Nucl Med Mol Imaging. 2023;50(11):3390\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"7341_CR31","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1007\/s00259-019-04448-8","volume":"46","author":"H Ilhan","year":"2019","unstructured":"Ilhan H, et al. First-in-human (18)F-SiFAlin-TATE PET\/CT for NET imaging and theranostics. Eur J Nucl Med Mol Imaging. 2019;46(11):2400\u20131.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7341_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.eprac.2022.10.002","volume":"29","author":"L Sandow","year":"2023","unstructured":"Sandow L, et al. Paraganglioma of the Head and Neck: A Review. Endocr Pract. 2023;29(2):141\u20137.","journal-title":"Endocr Pract"},{"key":"7341_CR33","doi-asserted-by":"publisher","first-page":"1021420","DOI":"10.3389\/fendo.2022.1021420","volume":"13","author":"G Constantinescu","year":"2022","unstructured":"Constantinescu G, et al. Silent pheochromocytoma and paraganglioma: Systematic review and proposed definitions for standardized terminology. Front Endocrinol (Lausanne). 2022;13:1021420.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"20","key":"7341_CR34","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"issue":"2","key":"7341_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5603\/NMR.2014.0022","volume":"17","author":"A d'Amico","year":"2014","unstructured":"d\u2019Amico A, et al. Effect of furosemide administration before F-18 fluorodeoxyglucose positron emission tomography\/computed tomography on urine radioactivity and detection of uterine cervical cancer. Nucl Med Rev Cent East Eur. 2014;17(2):83\u20136.","journal-title":"Nucl Med Rev Cent East Eur"},{"issue":"3","key":"7341_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1530\/EJE-14-0730","volume":"172","author":"D Weismann","year":"2015","unstructured":"Weismann D, et al. Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. Eur J Endocrinol. 2015;172(3):251\u201360.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"7341_CR37","first-page":"69","volume":"38","author":"G Eisenhofer","year":"2017","unstructured":"Eisenhofer G, et al. Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing. Clin Biochem Rev. 2017;38(2):69\u2013100.","journal-title":"Clin Biochem Rev"},{"issue":"5","key":"7341_CR38","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/cen.12542","volume":"81","author":"ND Niemeijer","year":"2014","unstructured":"Niemeijer ND, et al. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;81(5):642\u201351.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"7341_CR39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2967\/jnumed.118.211706","volume":"60","author":"S Han","year":"2019","unstructured":"Han S, et al. Performance of <sup>68<\/sup>Ga-DOTA\u2013Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis. J Nucl Med. 2019;60(3):369\u201376.","journal-title":"J Nucl Med"},{"issue":"3","key":"7341_CR40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1210\/endrev\/bnae001","volume":"45","author":"H Timmers","year":"2024","unstructured":"Timmers H, et al. Imaging of Pheochromocytomas and Paragangliomas. Endocr Rev. 2024;45(3):414\u201334.","journal-title":"Endocr Rev"},{"issue":"10","key":"7341_CR41","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1210\/clinem\/dgad166","volume":"108","author":"A Fischer","year":"2023","unstructured":"Fischer A, et al. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses. J Clin Endocrinol Metab. 2023;108(10):2676\u201385.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"7341_CR42","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1210\/jc.2019-00018","volume":"104","author":"G Kong","year":"2019","unstructured":"Kong G, et al. The Role of 68Ga-DOTA-Octreotate PET\/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab. 2019;104(11):5091\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"7341_CR43","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","volume":"21","author":"I Janssen","year":"2015","unstructured":"Janssen I, et al. Superiority of [68Ga]-DOTATATE PET\/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2015;21(17):3888\u201395.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"7341_CR44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","volume":"20","author":"D Ta\u00efeb","year":"2024","unstructured":"Ta\u00efeb D, et al. Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement. Nat Rev Endocrinol. 2024;20(3):168\u201384.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"7341_CR45","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","volume":"11","author":"D Ta\u00efeb","year":"2023","unstructured":"Ta\u00efeb D, et al. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Lancet Diabetes Endocrinol. 2023;11(5):345\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"7341_CR46","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.bpg.2012.12.006","volume":"26","author":"G Kanakis","year":"2012","unstructured":"Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol. 2012;26(6):791\u2013802.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"9","key":"7341_CR47","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","volume":"17","author":"IM Modlin","year":"2010","unstructured":"Modlin IM, et al. Chromogranin A\u2013biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17(9):2427\u201343.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"7341_CR48","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00259-017-3833-y","volume":"45","author":"V Amodru","year":"2018","unstructured":"Amodru V, et al. Quantitative (18)F-DOPA PET\/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. Eur J Nucl Med Mol Imaging. 2018;45(2):278\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7341_CR49","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000491578","volume":"107","author":"S Moog","year":"2018","unstructured":"Moog S, et al. 18F-FDOPA PET\/CT Uptake Parameters Correlate with Catecholamine Secretion in Human Pheochromocytomas. Neuroendocrinology. 2018;107(3):228\u201336.","journal-title":"Neuroendocrinology"},{"issue":"10","key":"7341_CR50","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1210\/jc.2009-1054","volume":"94","author":"HB Fiebrich","year":"2009","unstructured":"Fiebrich HB, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 2009;94(10):3922\u201330.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07341-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07341-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07341-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:04:16Z","timestamp":1762329856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07341-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":50,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7341"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07341-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed according to the Declaration of Helsinki (1991) and was approved by the local ethics committee (Medical Faculty, LMU Munich, Munich, Germany, application number 379\u201310). Written informed consent was obtained from every participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"MB received speaker honoraria from Roche, Iba, GE healthcare and Life Molecular Imaging, is an active advisor of MIAC, and advised GE Healthcare Life Molecular Imaging. RAW received speaker honoraria from Novartis\/AAA and PentixaPharm and reports advisory board work for Novartis\/AAA and Bayer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}